Lotus Eye Hospit

Who are the top shareholders of the Lotus Eye Hospit?

The top shareholders of Lotus Eye Hospital are Sangeetha S with 18.95%, followed by Kovai Purani Finance Private Limited at 6.67%. Individual investors hold a combined 40.95%, with no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Lotus Eye Hospital include Sangeetha S, who holds the largest stake at 18.95%. Following her, Kovai Purani Finance Private Limited is the highest public shareholder with a 6.67% ownership. Additionally, individual investors collectively hold 40.95% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

What does Lotus Eye Hospit do?

Lotus Eye Hospital & Institute Ltd is a micro-cap trust hospital specializing in eye care, with a recent quarterly net sales of 12 Cr and a net profit of 0 Cr as of March 2025. The company has a market cap of Rs 146 Cr and operates from Coimbatore, Tamil Nadu.

Overview: <BR>Lotus Eye Hospital & Institute Ltd is a trust hospital operating in the micro-cap segment of the healthcare industry.<BR><BR>History: <BR>The company was originally incorporated as "Kalaivani Health Centre Pvt. Limited" in 1997, changed its name to "Lotus Eye Care Hospital Pvt. Limited" in 2006, converted to a Public Limited Company in 2007, and was renamed to Lotus Eye Hospital & Institute Limited in 2013. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 12 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 146 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 149.00 <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.08 <BR>Return on Equity: 1.21% <BR>Price to Book: 2.47<BR><BR>Contact Details: <BR>Address: SF No770/12 Civil Aerodrome(P), Avinashi Road Coimbatore Tamil Nadu : 641014 <BR>Tel: 91-0422 4229900 <BR>Email: lotussecdept@gmail.com <BR>Website: http://www.lotuseye.org

When is the next results date for Lotus Eye Hospit?

No Upcoming Board Meetings

Has Lotus Eye Hospit declared dividend?

Lotus Eye Hospital & Institute Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of September 18, 2023. Despite the dividend declaration, the dividend yield is 0%, and total returns have varied across different periods, showing significant gains over the long term.

Lotus Eye Hospital & Institute Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 18 Sep 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -3.66%, the dividend return was 0%, resulting in a total return of -3.66%.<BR><BR>For the 1-year period, the price return was 26.61%, the dividend return was 0%, leading to a total return of 26.61%.<BR><BR>Over the 2-year period, the price return was -7.97%, the dividend return was 0.62%, resulting in a total return of -7.35%.<BR><BR>In the 3-year period, the price return was 46.37%, the dividend return was 1.99%, culminating in a total return of 48.36%.<BR><BR>For the 4-year period, the price return was 53.89%, the dividend return was 2.77%, leading to a total return of 56.66%.<BR><BR>In the 5-year period, the price return was 199.28%, the dividend return was 4.76%, resulting in a total return of 204.04%.<BR><BR>Overall, while Lotus Eye Hospital & Institute Ltd has declared a dividend, the dividend yield remains at 0%. The total returns over various periods show a mixed performance, with significant gains over longer periods, particularly in the 5-year span.

Is Lotus Eye Hospit overvalued or undervalued?

As of May 30, 2025, Lotus Eye Hospital & Institute Ltd. is considered very expensive and overvalued, with a high PE ratio of 148.28 and a low return on equity of 1.21%, indicating that its current stock price of 74.41 is not justified despite strong past stock performance.

As of 30 May 2025, the valuation grade for Lotus Eye Hospital & Institute Ltd. has moved from risky to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, as evidenced by its high PE ratio of 148.28, an EV to EBIT of 143.74, and an EV to EBITDA of 41.66, which are substantially above industry norms. <BR><BR>When compared to its peers, Lotus Eye Hospital's valuation metrics stand out unfavorably; for instance, its PE ratio is significantly higher than the industry average, suggesting that investors are paying a premium for its earnings. Additionally, the company's return on equity (ROE) is a mere 1.21%, which raises concerns about its profitability relative to its valuation. Despite a strong performance in stock returns over the past year, outpacing the Sensex, the current valuation metrics suggest that the stock is not justified at its current price of 74.41.

What is the technical trend for Lotus Eye Hospit?

As of June 4, 2025, Lotus Eye Hospital's technical trend is mildly bullish, supported by a bullish weekly MACD and Bollinger Bands, despite mixed signals from monthly indicators and a mildly bearish weekly Dow Theory.

As of 4 June 2025, the technical trend for Lotus Eye Hospit has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, supporting a positive outlook. Daily moving averages are also mildly bullish. However, the Dow Theory shows a mildly bearish stance on the weekly chart, contrasting with a mildly bullish monthly view. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands, despite some bearish signals in the monthly indicators.

Who are the peers of the Lotus Eye Hospit?

Lotus Eye Hospit's peers include Aashka Hospitals, Fortis Malar, Shanmuga Hospital, and others, with varying management risks and growth rates. Lotus Eye Hospit has a 1-year return of 10.19%, higher than Aashka Hospitals' -18.88% but lower than Shanmuga Hospital's return.

Peers: The peers of Lotus Eye Hospit are Aashka Hospitals, Fortis Malar, Shanmuga Hos., KK Shah Hospital, Vaidya Sane, Maitreya Medica., Sangani Hospital, KHFM Hospitality, Nephro Care, and Aatmaj Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shanmuga Hos. and Nephro Care, while Average management risk is found at Lotus Eye Hospit and Maitreya Medica. Below Average management risk is noted at Aashka Hospitals, Fortis Malar, KK Shah Hospital, Vaidya Sane, Sangani Hospital, and KHFM Hospitality. Growth is Excellent at Nephro Care, Good at Vaidya Sane and Aatmaj Health, Average at Lotus Eye Hospit and Maitreya Medica, and Below Average at the rest. Capital Structure is Good at Lotus Eye Hospit, KK Shah Hospital, Vaidya Sane, Maitreya Medica, Sangani Hospital, and Aatmaj Health, while it is Excellent at Shanmuga Hos. and Below Average at the remaining peers.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Shanmuga Hos. with N/A, while Aashka Hospitals has the lowest at -18.88%. Lotus Eye Hospit's 1-year return is 10.19%, which is higher than Aashka Hospitals but lower than Shanmuga Hos. Additionally, peers with a negative six-month return include Aashka Hospitals and Fortis Malar.

Who are in the management team of Lotus Eye Hospit?

As of March 2018, the management team of Lotus Eye Hospital includes S K Sundaramoorthy (Chairman cum Managing Director), Sangeetha Sundaramoorthy (Whole Time Director), and several non-executive independent directors, along with a Company Secretary. The team combines both executive and non-executive roles for effective governance.

As of March 2018, the management team of Lotus Eye Hospit includes the following individuals:<BR><BR>1. S K Sundaramoorthy - Chairman cum Managing Director<BR>2. Sangeetha Sundaramoorthy - Whole Time Director<BR>3. Kavetha Sundaramoorthy - Promoter & Non-Executive Director<BR>4. S S Badrinath - Non-Executive Independent Director<BR>5. D R Kaarthikeyan - Non-Executive Independent Director<BR>6. Yogesh Shah - Non-Executive Independent Director<BR>7. G R Karthikeyan - Non-Executive Independent Director<BR>8. R Subramanian - Non-Executive Independent Director<BR>9. M Alagiriswamy - Non-Executive Independent Director<BR>10. PR Rangaswami - Alternate Director to Kavetha Sundaramoorthy<BR>11. Aakanksha Parmar - Company Secretary & Compliance Officer<BR><BR>This team comprises a mix of executive and non-executive members, contributing to the governance and management of the company.

How big is Lotus Eye Hospit?

As of 24th July, Lotus Eye Hospital & Institute Ltd has a market capitalization of 153.00 Cr and reported net sales of 49.56 Cr and a net profit of 0.73 Cr over the latest four quarters. Shareholder's funds are 59.41 Cr, with total assets of 66.32 Cr as of March 2024.

As of 24th July, <BR><BR>Market Cap: Lotus Eye Hospital & Institute Ltd has a market capitalization of 153.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 49.56 Cr, while the sum of Net Profit for the same period is 0.73 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 59.41 Cr and Total Assets totaling 66.32 Cr.

How has been the historical performance of Lotus Eye Hospit?

Lotus Eye Hospital has experienced revenue growth from INR 32.37 crore in March 2021 to INR 49.56 crore in March 2025, but profitability has declined, with profit after tax dropping from INR 4.08 crore to INR 0.74 crore during the same period, alongside decreasing cash flow. Total assets and liabilities have both increased, indicating financial strain despite rising sales.

Answer:<BR>The historical performance of Lotus Eye Hospital shows a mixed trend over the years, with fluctuations in revenue and profit metrics.<BR><BR>Breakdown:<BR>Lotus Eye Hospital's net sales have shown a steady increase from INR 32.37 crore in March 2021 to INR 49.56 crore in March 2025, with a notable rise from INR 38.91 crore in March 2022. Total operating income has mirrored this trend, reaching INR 49.56 crore in March 2025. However, the total expenditure has also increased significantly, from INR 28.81 crore in March 2021 to INR 46.13 crore in March 2025, impacting operating profit, which fell from INR 7.58 crore in March 2023 to INR 3.43 crore in March 2025. Consequently, profit before tax decreased from INR 5.65 crore in March 2023 to INR 1.38 crore in March 2025, with profit after tax also declining from INR 4.08 crore to INR 0.74 crore during the same period. The company's total assets rose from INR 57.26 crore in March 2020 to INR 69.49 crore in March 2025, while total liabilities increased from INR 58.46 crore to INR 69.49 crore. Cash flow from operating activities decreased from INR 5 crore in March 2024 to INR 2 crore in March 2025, contributing to a net cash outflow of INR 5 crore in March 2025, compared to a net outflow of INR 2 crore in March 2024. Overall, while revenue has grown, profitability and cash flow have faced challenges in recent years.

Are Lotus Eye Hospital & Institute Ltd latest results good or bad?

Lotus Eye Hospital & Institute Ltd's latest Q3 FY26 results are concerning, showing a net loss of ₹0.26 crores despite a 10.61% revenue growth to ₹13.55 crores, with declining profitability metrics and a low return on equity of 1.10%. Overall, the financial performance indicates significant risks for investors.

Lotus Eye Hospital & Institute Ltd's latest results for Q3 FY26 indicate a challenging financial situation. The company reported a net loss of ₹0.26 crores, marking a loss-making quarter and a decline from a loss of ₹0.24 crores in the same quarter last year. While the revenue grew by 10.61% year-on-year to ₹13.55 crores, this growth is overshadowed by significant profitability issues.<BR><BR>The operating margin has decreased to 4.80% from 6.53% a year earlier, reflecting increased cost pressures. Additionally, the return on equity (ROE) stands at a very low 1.10%, indicating weak capital efficiency. The company's financial performance suggests that despite revenue growth, it is struggling to convert that into sustainable profits, raising concerns about its operational viability.<BR><BR>Overall, the results can be characterized as bad due to the persistent losses and declining profitability metrics, despite some positive revenue growth. Investors should be cautious, as the disconnect between the company's market valuation and its operational performance presents significant risks.

Which are the latest news on Lotus Eye Hospit?

Should I buy, sell or hold Lotus Eye Hospital & Institute Ltd?

Why is Lotus Eye Hospital & Institute Ltd falling/rising?

As of 08-May, the stock price of Lotus Eye Hospital & Institute Ltd is at 115.05, reflecting a decline of 2.95%. The stock has underperformed its sector and shows a negative trend, with decreased investor participation and short-term weakness indicated by moving averages.

As of 08-May, the stock price of Lotus Eye Hospital & Institute Ltd is falling, currently at 115.05, which reflects a decrease of 3.5 or 2.95%. This decline is evident in today's performance, where the stock underperformed its sector by 4.75% and opened with a loss of 3.84%. The stock also reached an intraday low of Rs 114, indicating significant selling pressure.<BR><BR>In terms of recent performance, the stock has shown a negative trend over the past week, with a decline of 3.20%, while the benchmark Sensex has increased by 0.54%. Year-to-date, the stock is down 2.95%, contrasting with a more substantial decline of 9.26% in the Sensex. Additionally, the stock has experienced a drop in investor participation, with delivery volume falling by 14.29% compared to the 5-day average, suggesting reduced interest from investors.<BR><BR>Despite being above the 20-day, 50-day, and 200-day moving averages, the stock is below the 5-day and 100-day moving averages, indicating a short-term weakness. Overall, these factors contribute to the stock's current downward trajectory.